TY - JOUR
T1 - Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice
AU - Reinhard, Judith R.
AU - Lin, Shuo
AU - McKee, Karen K.
AU - Meinen, Sarina
AU - Crosson, Stephanie C.
AU - Sury, Maurizio
AU - Hobbs, Samantha
AU - Maier, Geraldine
AU - Yurchenco, Peter D.
AU - Rüegg, Markus A.
N1 - Funding Information:
This work was supported by the Cantons of Basel-Stadt and Basel-Landschaft, grants from the Swiss Foundation for Research on Muscle Diseases, the Association Française contre les Myopathies, and the Neuromuscular Research Association Basel.
Publisher Copyright:
© Copyright 2017 The Authors, some rights reserved.
PY - 2017/6/28
Y1 - 2017/6/28
N2 - LAMA2-related muscular dystrophy (LAMA2 MD or MDC1A) is the most frequent form of early-onset, fatal congenital muscular dystrophies. It is caused by mutations in LAMA2, the gene encoding laminin-α2, the long arm of the heterotrimeric (α2, β1, and γ1) basement membrane protein laminin-211 (LM-211). We establish that despite compensatory expression of laminin-α4, giving rise to LM-411 (α4, β1, and γ1), muscle basement membrane is labile in LAMA2 MD biopsies. Consistent with this deficit, recombinant LM-411 polymerized and bound to cultured myotubes only weakly. Polymerization and cell binding of LM-411 were enhanced by addition of two specifically designed linker proteins. One, called αLNNd, consists of the N-terminal part of laminin-α1 and the laminin-binding site of nidogen-1. The second, called mini-agrin (mag), contains binding sites for laminins and α-dystroglycan. Transgenic expression of mag and αLNNd in a mouse model for LAMA2 MD fully restored basement membrane stability, recovered muscle force and size, increased overall body weight, and extended life span more than five times to a maximum survival beyond 2 years. These findings provide a mechanistic understanding of LAMA2 MD and establish a strong basis for a potential treatment.
AB - LAMA2-related muscular dystrophy (LAMA2 MD or MDC1A) is the most frequent form of early-onset, fatal congenital muscular dystrophies. It is caused by mutations in LAMA2, the gene encoding laminin-α2, the long arm of the heterotrimeric (α2, β1, and γ1) basement membrane protein laminin-211 (LM-211). We establish that despite compensatory expression of laminin-α4, giving rise to LM-411 (α4, β1, and γ1), muscle basement membrane is labile in LAMA2 MD biopsies. Consistent with this deficit, recombinant LM-411 polymerized and bound to cultured myotubes only weakly. Polymerization and cell binding of LM-411 were enhanced by addition of two specifically designed linker proteins. One, called αLNNd, consists of the N-terminal part of laminin-α1 and the laminin-binding site of nidogen-1. The second, called mini-agrin (mag), contains binding sites for laminins and α-dystroglycan. Transgenic expression of mag and αLNNd in a mouse model for LAMA2 MD fully restored basement membrane stability, recovered muscle force and size, increased overall body weight, and extended life span more than five times to a maximum survival beyond 2 years. These findings provide a mechanistic understanding of LAMA2 MD and establish a strong basis for a potential treatment.
UR - http://www.scopus.com/inward/record.url?scp=85021682724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021682724&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aal4649
DO - 10.1126/scitranslmed.aal4649
M3 - Article
C2 - 28659438
AN - SCOPUS:85021682724
SN - 1946-6234
VL - 9
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 396
M1 - eaal4649
ER -